Therefore, the independence of our academic HRD pipelines in relation to the BRCA1/2 testing could facilitate the assay implementation: a patient diagnostic pathway based on the HRD screening, followed by BRCA1/2 tumor and germline testing (reflex modality), could significantly reduce the issues related to the errors in BRCA1/2 assessment which are still affecting the different commercial and in-house pipelines [11,19,20,21]. This evidence concerns the gene BRCA1 and neoplasm.